ERBB2 and breast cancer: Site-specific conjugation of the small moleculedrug to the antibody homogenizes the mixture of ADCs, thus providingmore reliable pharmacokinetic properties, efficacy, and safety profiles.In 2014, Tian and co-workers produced gram per liter scale titersof UAA-incorporated ADCs from stable CHO cells using antibodies targetingcommon antigens on colorectal/gastric and breast cancers.113 Ambrx, Inc., developed an anti-HER2 ADC productARX788 using the UAA incorporation strategy.